Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active ankylosing spondylitis: randomized double-blind placebo-controlled phase III trial
2013-001090-24Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Secukinumab with Placebo (2 arms). Primary endpoint: ASAS 20 response at week 16. Started Oct 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2013-001090-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001090-24.